Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29536213 | 1.00 | KDM4E (0.46) | KDM4ESMN1; SMN2LMNAPOLBALDH1A1 | |
| SCHEMBL18068165 | 0.84 | KDM4E (0.47) | KDM4ESMN1; SMN2LMNAPOLBALDH1A1 | |
| SCHEMBL17979201 | 0.83 | KDM4E (0.46) | KDM4ESMN1; SMN2LMNAPOLBALDH1A1 | |
| SCHEMBL29514766 | 0.80 | KDM4E (0.46) | KDM4ESMN1; SMN2LMNAPOLBALDH1A1 | |
| SCHEMBL22527929 | 0.80 | KDM4E (0.46) | KDM4ESMN1; SMN2LMNAPOLBALDH1A1 | |
| SCHEMBL17979256 | 0.80 | KDM4E (0.43) | KDM4ESMN1; SMN2LMNAPOLBALDH1A1 | |
| SCHEMBL4650346 | 0.78 | TUBB4A (0.47) | KDM4ESMN1; SMN2LMNAPOLBALDH1A1 | |
| SCHEMBL22528095 | 0.77 | KDM4E (0.40) | KDM4ESMN1; SMN2LMNAPOLBALDH1A1 | |
| SCHEMBL29614456 | 0.77 | KDM4E (0.40) | KDM4ESMN1; SMN2LMNAPOLBALDH1A1 | |
| SCHEMBL18018471 | 0.72 | PDE10A (0.34) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485144-B2 | 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof | NURIX THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| CN-114364670-B | Substituted benzyl-triazole compound for Cbl-b inhibition and further application thereof | 纽力克斯治疗公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20250136590-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | NURIX THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| US-12234230-B2 | Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof | NURIX THERAPEUTICS, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| CN-114364667-B | 3-Substituted piperidines for Cbl-b inhibition and use of Cbl-b inhibitors in combination with cancer vaccines and/or oncolytic viruses | 紐力克斯治疗公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20240409555-A1 | CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF | NURIX THERAPEUTICS, INC. | 2024-12-12 | — | — | US | disclosed |
| CN-114206855-B | Cyanocyclobutyl compounds for Cbl-b inhibition and application thereof | 紐力克斯治疗公司 | 2024-11-26 | — | — | CN | disclosed |
| US-20240293458-A1 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE THEREOF | NURIX THERAPEUTICS, INC. | 2024-09-05 | — | — | US | disclosed |
| US-12049471-B2 | Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof | NURIX THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-11951133-B2 | 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof | NURIX THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| EP-3256463-B1 | 1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2019-10-09 | — | — | EP | disclosed |
| EP-3256463-B1 | 1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2019-10-09 | — | — | EP | disclosed |
| US-10179782-B2 | Substituted sulfonamide compounds | GENENTECH, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-10179782-B2 | Substituted sulfonamide compounds | GENENTECH, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| EP-3256463-A1 | 1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2017-12-20 | — | — | EP | disclosed |
| US-20160264567-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264567-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264567-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2016128529-A1 | 1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016128529-A1 | 1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179782-B2 | Substituted sulfonamide compounds | TRPA1, TRPV1, TRPV5 | KDM4E 3746/4885SMN1; SMN2 1143/4885LMNA 2609/4885 |
| US-12049471-B2 | Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof | CBLB, CBL, CBLC | KDM4E 736/4885SMN1; SMN2 2986/4885LMNA 1984/4885 |
| US-11951133-B2 | 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof | CBLB, CBL, CBLC | KDM4E 317/4885SMN1; SMN2 2589/4885LMNA 1711/4885 |
| US-20240409555-A1 | CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF | CBLB, CBL, CBLC | KDM4E 736/4885SMN1; SMN2 2986/4885LMNA 1984/4885 |
| US-12485144-B2 | 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof | CBLB, CBL, CBLC | KDM4E 317/4885SMN1; SMN2 2589/4885LMNA 1711/4885 |
| US-12234230-B2 | Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof | CBL, CBLB, CBLC | KDM4E 744/4885SMN1; SMN2 3521/4885LMNA 2268/4885 |
| US-20250136590-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | CBL, CBLB, CBLC | KDM4E 744/4885SMN1; SMN2 3521/4885LMNA 2268/4885 |
| US-20240293458-A1 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE THEREOF | CBLB, CBL, CBLC | KDM4E 317/4885SMN1; SMN2 2589/4885LMNA 1711/4885 |
| US-20160264567-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | TRPA1, TRPV1, TRPV5 | KDM4E 3746/4885SMN1; SMN2 1143/4885LMNA 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.